Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.46 |
| ▸ | CDK9 | P50750 | 7/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825123 | 0.77 | ALDH1A1 (0.39) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL4028536 | 0.76 | CDK9 (0.45) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL13847790 | 0.69 | CDK9 (0.51) | CDK9CDK2AKT1MEN1KMT2A | |
| SCHEMBL4031312 | 0.68 | SLC40A1 (0.42) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL14287940 | 0.68 | CCNT1 (0.50) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL4034066 | 0.68 | CCNT1 (0.38) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL4033384 | 0.67 | SLC40A1 (0.45) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL13202876 | 0.65 | CDK9 (1.00) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL13202878 | 0.64 | CDK9 (0.80) | CCNT1CDK9CCNA2CDK2CCNA1 | |
| SCHEMBL13848030 | 0.63 | CDK9 (0.66) | CCNT1CDK9CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | claimed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | claimed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | claimed |
| EP-1307454-B1 | DERIVATIVES OF VARIOLIN B | PHARMA MAR SA (ES) | 2009-06-03 | — | — | EP | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033001-A1 | Derivatives of Variolin B | ARG2, SDHB, OAT | CCNT1 407/4885CDK9 1601/4885CCNA2 78/4885 |
| US-20040058939-A1 | Derivatives of variolin b | HNRNPA2B1, HNRNPAB, SYNCRIP | CCNT1 678/4885CDK9 2228/4885CCNA2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.